8-K: DNA X, Inc. Secures Funding Amidst Nasdaq Delisting Threat

DNA X, Inc. has entered into a Securities Purchase Agreement to issue a convertible note, while simultaneously facing a potential delisting from the Nasdaq Capital Market.

Summary

• DNA X, Inc. has entered into a Securities Purchase Agreement with DNA Holdings Venture, Inc. to issue a convertible promissory note for $3,052,787.68.
• The purchase price was comprised of $1,800,000.00 in cash and the surrender of a prior convertible note valued at $1,200,000.00 plus $52,787.68 in accrued interest.
• The proceeds are designated for working capital, excluding debt repayment, stock redemption, or litigation settlement.
• The note matures on December 31, 2026, with a 10% annual interest rate, and is convertible into common stock at $6.00 per share, subject to stockholder approval.
• The company is also facing a potential delisting from the Nasdaq Capital Market due to insufficient stockholders' equity and intends to appeal the determination.
• Trading suspension is scheduled for June 2, 2026, if a hearing is not requested by May 29, 2026.
• The company's obligations under the note are secured by a lien on its membership interests in its wholly-owned subsidiary, DNA X, LLC.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant risk of Nasdaq delisting, despite the successful issuance of a convertible note.

Positives

• Secured new financing through a convertible note, providing $3,052,787.68 in principal amount.
• The new financing includes a cash component of $1,800,000.00.
• The company has a clear plan to appeal the Nasdaq delisting determination, which will stay the suspension of trading pending a hearing.
• The convertible note is secured by the company's membership interests in its subsidiary, DNA X, LLC.

Negatives

• The company is at risk of delisting from the Nasdaq Capital Market due to failing to meet the stockholders' equity requirement.
• A delisting could make it more difficult to buy or sell the company's common stock and could lead to a material decline in its price.
• Delisting could impair the company's ability to raise capital and may trigger defaults under existing agreements.
• The conversion of the convertible note is contingent upon stockholder approval.

Risks

• Potential delisting from the Nasdaq Capital Market if the company fails to regain compliance with listing requirements.
• The outcome of the Nasdaq hearing panel appeal is uncertain.
• The company may not be able to regain compliance with Nasdaq's continued listing requirements.
• If delisted, the company's common stock price could suffer a material decline.
• Delisting could hinder the company's ability to raise future capital.
• The convertible note's conversion is subject to stockholder approval.
• The company's obligations under the note are secured by its subsidiary's membership interests, which could be foreclosed upon if the note is not repaid.

Future Outlook

The company is focused on appealing the Nasdaq delisting determination and intends to regain compliance with listing requirements. The convertible note is set to mature on December 31, 2026, and its conversion is subject to stockholder approval. The proceeds from the note are intended for working capital purposes.

Management Comments

• The Company intends to timely request a hearing before the Panel, at which it will request a suspension of delisting pending its return to compliance.
• There can be no assurance that the Company will be able to regain compliance with the Stockholders Equity Requirement or will otherwise be in compliance with other applicable Nasdaq listing rules, that the Panel will grant the Company's request for a suspension of delisting on Nasdaq, or that the Company's appeal of the delisting determination will be successful.

Industry Context

StockSavvy.ai notes that securing financing while facing potential delisting is a critical juncture for a company. The terms of the convertible note, including its conversion price and security, will be closely watched by investors. The company's ability to navigate the Nasdaq appeal process will be paramount to its continued market access and future fundraising capabilities.

Legal Proceedings

• The company is subject to potential delisting from the Nasdaq Capital Market due to failure to meet the Stockholders Equity Requirement.

Related Party Transactions

• The Securities Purchase Agreement and the issuance of the convertible note were made with DNA Holdings Venture, Inc., which is identified as the Purchaser.

Stakeholder Impact

• Shareholders: Potential for share price decline and difficulty in trading if delisted; conversion of note may dilute existing shareholders.
• Creditors: Delisting could trigger defaults and penalties under outstanding agreements.
• Suppliers: Potential impact on the company's ability to pay trade payables if financial distress deepens.

Next Steps

• The Company intends to request a hearing before the Nasdaq Hearing Panel to appeal the delisting determination.
• The Company will seek a suspension of delisting pending the conclusion of the hearing process.
• The Company must file a Form D with the SEC and applicable state securities regulators regarding the convertible note.

Key Dates

Recommendation

The company has secured necessary funding through a convertible note, which is positive. However, the immediate threat of Nasdaq delisting presents a significant risk that could severely impact the stock price and future capital raising abilities. A 'hold' recommendation reflects the balance between the immediate financing and the substantial ongoing risk of delisting, pending the outcome of the Nasdaq appeal.

Keywords

convertible note, securities purchase agreement, Nasdaq delisting, working capital, stockholder approval, secured financing, Form 8-K, DNA X, Inc.